The Fund is authorized to issue an unlimited number of transferable, redeemable units of one class. As the Fund is in the process of terminating, there are currently no redemption rights for unit holders. All units have equal rights and privileges, each of which represents an equal, undivided interest in the net assets of the Fund. Each whole unit is entitled to one vote at all meetings of unit holders and is entitled to participate equally with respect to any and all distributions made by the Fund and distributions upon the termination of the Fund.

ME Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.

Metalo Manufacturing Inc. (MMI) targets energy intensive sectors and the ownership of downstream production facilities with near-zero CO2 emissions as the driving force behind their modeling. 

Further, MMI is dedicated to the integration of Canadian minerals and value-add through low-cost and clean electricity. 

​MMI is currently a large shareholder in two development projects:

​Pure Fonte Ltée:  MMI continues to advance the measured development of a Pig Iron production plant for steel mills and foundries. This will be unique globally using hydroelectricity as the source of energy, with near-zero CO2 emissions.  Electric Arc Furnace steel mills and iron foundries committed to lowering their CO2 footprint will benefit from this midstream material.  Additionally, the plant has been engineered to be converted to making a green steel if required.

Labrador Sands Inc:  MMI’s second asset is a mineral sands resource near a Canadian seaport with two key and low-cost minerals (feldspars and silica quartz) and their confirmed grades and uses to make glass and ceramic products. The sands will be combined with low-cost and clean electricity to produce a range of energy -intensive products with near-zero CO2 emissions. Production Plants will see a joint venture structure with known operators applied for each production plant including sanitary ware, silicon carbide (made with a biomass), ceramic tiles and tableware, glass products (containers, vials, fiberglass, wool, etc.) and 3D printing. Canada is nearly 100% import dependent on these products.

Collectively, more than $50 million has been invested in assessing and defining market solutions. One asset has a Bankable Feasibility Study and the other a Preliminary Economic Assessment. 

MMI’s holding in the two projects is through Grand River Ironsands Incorporated (privately held), where MMI controls 44% of the shares.

Moss Genomics Inc. is an emerging consumer genomics company that offers personalized health, anti-aging and wellness offerings guided by genomic, microbiome, and epigenome data. The Company intends to eliminate barriers in healthcare by offering easy-access, at-home, affordable testing paired with easy-to-understand actionable results.